- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06323980
INHANCE IDE de hombro inverso sin tallo
Estudio multicéntrico, prospectivo y aleatorizado del sistema de hombro inverso total sin vástago INHANCE
2:1 Randomized, Controlled, Multi-Center, Prospective, Pre-Market Study of the INHANCE Stemless Reverse Cementless Total Shoulder.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
There is one primary effectiveness endpoint and there are three primary safety endpoints:
-
Primary effectiveness endpoint - Adjusted Constant-Murley Change from Baseline (ACM CFB) at 2 years post-operative
-
Primary safety endpoint(s):
- No revision, removal, reoperation, supplemental fixation, or other intervention for any system component
- No humeral or glenoid radiolucent line >2 mm is present in 50% or more zones at 2 years
- No conclusive evidence of migration and tilt (>5mm migration and >10° tilt) of the humeral or glenoid component at 2 years
The study will be successful if the primary effectiveness endpoint non-inferiority analysis is successfully demonstrated, and no significant difference is seen on any of the 3 primary safety endpoints.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Florida
-
Atlantis, Florida, Estados Unidos, 33462
- Orthopedic Center of Palm Beach County
-
-
Massachusetts
-
Waltham, Massachusetts, Estados Unidos, 02451
- Boston Bone & Joint Institute BBJI Formerly BSSC
-
-
Michigan
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Trinity Health Grand Rapids
-
-
Missouri
-
Columbia, Missouri, Estados Unidos, 65201
- Missouri Orthopaedic Institute (MOI)
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28207
- OrthoCarolina Research Institute Charlotte
-
Raleigh, North Carolina, Estados Unidos, 27609
- Duke Orthopaedics of Raleigh
-
-
Ohio
-
Akron, Ohio, Estados Unidos, 44333
- Crystal Clinic Orthopaedic Center
-
Cincinnati, Ohio, Estados Unidos, 45219
- Lindner Research Center
-
Cleveland, Ohio, Estados Unidos, 44195
- The Cleveland Clinic Foundation
-
-
Oregon
-
Eugene, Oregon, Estados Unidos, 97401
- Slocum Center for Orthopaedics and Sports Medicine
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Estados Unidos, 18015
- St. Luke's University Health Network
-
Philadelphia, Pennsylvania, Estados Unidos, 19107
- Rothman Orthopaedics Institute
-
-
Tennessee
-
Columbia, Tennessee, Estados Unidos, 38401
- MTBJ a division of Tennessee Orthaepedic Alliance
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84108
- University of Utah
-
-
Virginia
-
Fredericksburg, Virginia, Estados Unidos, 22408
- Mary Washington Orthopedics in affiliation with FOA
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Individuals requiring reverse total shoulder replacement for a severely painful, disabling, arthritic joint (i.e. osteoarthritis, post-traumatic arthritis and rotator cuff arthropathy).
- Individuals who are anatomically and structurally suited to receive the implants and have a functional deltoid muscle.
- Individuals who are able to read and comprehend the informed patient consent document and are willing and able to provide informed patient consent for participation in the study and have authorized the transfer of their information to DePuy Synthes.
- Individuals who are willing and able to return for follow-up as specified by the study protocol.
- Individuals who are a minimum age of 22 years at the time of consent.
- Individuals who are willing and able to complete the Patient Reported Outcome Measure questionnaires (PROMs) as specified by the study protocol.
Exclusion Criteria:
- BMI > 40 kg/m2
- Individuals have active, uncontrolled local infection or systemic infection.
- Patients who have not reached skeletal maturity, regardless of age.
- Either preoperatively or intraoperatively and per standard of care medical assessment, bone stock in the proximal humerus or glenoid fossa is determined to be inadequate for supporting the INHANCE humeral stemless components (NOTE: exclusion applies to both arms of the study, i.e., bone stock to be evaluated independent of randomized treatment assignment).
- Intraoperatively and per treating physician's assessment of bone quality, bone is determined to be too soft or porous to support the implant or that is too hard or brittle to allow for proper bone preparation and fixation, i.e. osteoporosis or sclerotic bone, or tumor(s) of the supporting bone structure, where there could be considerable migration of the prosthesis and/or a chance of fracture of the humerus or glenoid.
- Fractures of the proximal humerus that could compromise the fixation of the INHANCE reverse humeral stemless components.
- Patients who have undergone previous treatment on the study shoulder that may compromise fixation of the INHANCE reverse humeral stemless component.
- Revision of a failed hemi, total or reverse shoulder arthroplasty.
- Patient is receiving, or is scheduled to receive, treatment that the Investigator considers could affect bone quality, such as chemotherapy or high dose corticosteroids.
- Individuals who are bedridden per the Investigator's determination.
- Individuals that have participated in a clinical investigation with an investigational product (drug or device) in the last three months.
- Individuals currently involved in any personal injury litigation, medical-legal or worker's compensation claims.
- Individuals, in the opinion of the Investigator, who are drug or alcohol abusers or have psychological disorders that could affect their ability to complete patient reported questionnaires or be compliant with follow-up requirements.
- Patients with a known medical condition that the Investigator believes would impact the study outcomes (including, but not limited to osteomyelitis, Paget's disease, neuropathies such as Charcot's disease, metastatic or neoplastic disorders).
- Patient has a medical condition with less than 2 years life expectancy.
- Patients who are known to be pregnant or breastfeeding.
- Known polyethylene and/or metal sensitivity or allergy.
- Contralateral side has been enrolled in the study or has received a total shoulder operation within the last 6 months
- Otherwise determined by the investigator to be medically unsuitable for participation in this study
- Patient is a member of a vulnerable population (i.e., incarcerated individuals - those incarcerated for at least one month and considered to be an inmate)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: INHANCE Stemless Reverse
INHANCE(TM) Stemless Reverse Total Shoulder |
Uncemented Reverse Total Shoulder |
|
Comparador activo: INHANCE Stemmed Reverse
INHANCE(TM) Stemmed Reverse Total Shoulder |
Uncemented Reverse Total Shoulder |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Constant Murley Score (CMS)
Periodo de tiempo: Pre-op, 2 years
|
Primary effectiveness endpoint - Adjusted Constant-Murley Change from Baseline (ACM CFB) at 2 years post-operative. The CMS is a 100 point scale, the higher the score, the higher the quality of the function. ACM will be obtained by dividing the raw score by the relative score. |
Pre-op, 2 years
|
|
Removal of any system component
Periodo de tiempo: 2 year
|
No removal of any system component |
2 year
|
|
Revision of any system component
Periodo de tiempo: 2 year
|
No revision of any system component |
2 year
|
|
Reoperation of any system component
Periodo de tiempo: 2 year
|
No reoperation of any system component |
2 year
|
|
Supplemental Fixation of any system component
Periodo de tiempo: 2 year
|
No supplemental fixation of any system component |
2 year
|
|
Radiolucent Lines (Humeral & Glenoid)
Periodo de tiempo: 2 year
|
No humeral or glenoid radiolucent line greater than 2mm is present in 50% or more zones |
2 year
|
|
Migration and Tilt (Humeral & Glenoid)
Periodo de tiempo: 2 year
|
No conclusive evidence of migration and tilt (greater than 5mm migration and greater than 10 degrees tilt) of the humeral or glenoid component |
2 year
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Constant Murley Score (CMS)
Periodo de tiempo: Pre-op, 3-month, 6-month, 1 year, 2 year
|
Adjusted Constant-Murley Score at baseline and 3- and 6-months and 1- and 2-years post-operative. The CMS is a 100 point scale, the higher the score, the higher the quality of the function. ACM will be obtained by dividing the raw score by the relative score. |
Pre-op, 3-month, 6-month, 1 year, 2 year
|
|
EQ-5D-5L and EQ-VAS
Periodo de tiempo: Pre-op, 3-month, 6-month, 1 year, 2 year
|
EQ-5D-5L Scores by dimension and EQ-VAS, at baseline and 3- and 6-months and 1- and 2-years post-operative. The value score generally ranges from less than 0 to 1, with higher scores indicating higher health utility. The EQ VAS records the subject's self-rated health from 0 (worst) to 100 (best). |
Pre-op, 3-month, 6-month, 1 year, 2 year
|
|
Simple Shoulder Test
Periodo de tiempo: Pre-op, 3-month, 6-month, 1 year, 2 year
|
Simple Shoulder Test (SST) Scores at baseline and 3- and 6-months and 1- and 2-years post-operative. Scores range from 0 (worst) to 12 (best). |
Pre-op, 3-month, 6-month, 1 year, 2 year
|
|
Single Assessment Numeric Evaluation (SANE) Score
Periodo de tiempo: Pre-op, 3-month, 6-month, 1 year, 2 year
|
Single Assessment Numeric Evaluation (SANE) Scores at baseline and 3- and 6-months and 1- and 2-years post-operative. The scale is 0 to 100 with 100 being "normal". |
Pre-op, 3-month, 6-month, 1 year, 2 year
|
|
Survivorship
Periodo de tiempo: 2 year
|
Overall survivorship of the INHANCE Shoulder System at 2 years post-operative, where the system is deemed to be surviving if no components (humeral stem or stemless component, glenosphere, baseplate, liner, etc.) have been removed for any reason, will be presented using the Kaplan-Meier method. |
2 year
|
|
Complications
Periodo de tiempo: 2 year
|
The type and frequency of all reportable adverse events (AEs) and device deficiencies in this study will be summarized, with distinction of serious AEs, device and procedure related AEs |
2 year
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Constant Murley Score (CMS)
Periodo de tiempo: Pre-op, 3-month, 6-month, 1 year
|
Change from baseline adjusted Constant-Murley Score at 3- and 6-months and 1- year post-operative. The CMS is a 100 point scale, the higher the score, the higher the quality of the function. ACM will be obtained by dividing the raw score by the relative score. |
Pre-op, 3-month, 6-month, 1 year
|
|
EQ-5D-5L and EQ-VAS
Periodo de tiempo: Pre-op, 3-month, 6-month, 1 year, 2 year
|
Change from baseline EQ-5D-5L Value Score and EQ-VAS, at 3- and 6-months and 1- and 2-years post-operative. The value score generally ranges from less than 0 to 1, with higher scores indicating higher health utility. The EQ VAS records the subject's self-rated health from 0 (worst) to 100 (best). |
Pre-op, 3-month, 6-month, 1 year, 2 year
|
|
Simple Shoulder Test
Periodo de tiempo: Pre-op, 3-month, 6-month, 1 year, 2 year
|
Change from baseline SST Scores at 3- and 6-months and 1- and 2-years post-operative. Scores range from 0 (worst) to 12 (best). |
Pre-op, 3-month, 6-month, 1 year, 2 year
|
|
Single Assessment Numeric Evaluation (SANE) Score
Periodo de tiempo: Pre-op, 3-month, 6-month, 1 year, 2 year
|
Change from baseline SANE Scores at 3- and 6-months and 1- and 2-years post-operative. The scale is 0 to 100 with 100 being "normal". |
Pre-op, 3-month, 6-month, 1 year, 2 year
|
|
Range of Motion
Periodo de tiempo: Pre-op, 3-month, 6-month, 1 year, 2 year
|
Change from baseline range of motion at 3- and 6-months and 1- and 2-years post-operative |
Pre-op, 3-month, 6-month, 1 year, 2 year
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- DSM202108
- DSM202108 (Otro identificador: DePuy Orthopaedics)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .